Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the second in women ([@bib29]). To reduce the burden of CRC, various population screening programmes have been introduced ([@bib11]; [@bib12]; [@bib22]) aimed at reducing morbidity and mortality through early detection. One of these programs -- faecal immuno-chemical testing (FIT) can be achieved entirely through the postal system, with participants receiving a positive or negative result letter with follow-up advice.

However, studies have shown that those who test positive in such screening programmes experience elevated anxiety levels ([@bib20]; [@bib13]). Possible distress may also arise from receiving a false positive result, undergoing a follow-up colonoscopy or from anticipating an unfavourable diagnosis ([@bib5]; [@bib27]).

Although the anxiety elicited from CRC screening is well established, less is known about the impact of this type of screening on quality of life (QOL), self-efficacy, cancer risk perception and screening decision making, all of which have been shown to influence future screening intentions and uptake ([@bib18]; [@bib16]; [@bib8]). Therefore, this prospective cohort study aimed to determine the short- and long-term psychological consequences of receiving a positive or negative result in FIT-based CRC screening programmes in Australia at key points along the screening and diagnostic pathway.

Materials and methods
=====================

Colorectal cancer population screening in Australia
---------------------------------------------------

Population screening was introduced in 2008 through the National Bowel Cancer Screening Program (NBCSP). The NBCSP Register sends eligible people a pre-invitation letter followed by an invitation pack, which includes an immunochemical test kit for detection of faecal occult blood. Participants collect two faecal samples, which are mailed to the programme pathology laboratory for analysis. Test results are sent to the participant and their nominated general practitioner, and positive participants are advised to undergo diagnostic colonoscopy. Approximately 6% of participants who undergo this form of screening test positive ([@bib4]).

Study eligibility criteria
--------------------------

Study participants had to be aged 50--74 years when they completed CRC screening. The positive group had a positive FIT following a NBCSP screening test and had been referred to metropolitan public hospitals for diagnostic colonoscopy. The negative group had a negative FIT through a public hospital co-ordinated population screening research programme, which followed exactly the same screening process as the NBCSP.

Ethics approval for this study was granted by the Southern Adelaide Clinical Human Research Ethics Committee.

Study design
------------

Potential participants were mailed a study invitation, six questionnaires, a participant information sheet, an 'opt-out\' form and a reply paid envelope. Completion and return of the questionnaires indicated consent. Those who did not opt out or reply were sent a second and third reminder after 4 and 6 weeks of the initial mail-out ([@bib9]; [@bib10]).

Survey schedule
---------------

FIT positives were sent a set of questionnaires (1) after positive FIT result notification (ARN) but prior to undergoing colonoscopy; (2) after undergoing colonoscopy; and (3) at 12 months after the original result notification. FIT negatives were sent a set of questionnaires (1) after negative FIT result notification and (2) at 12 months after the original result notification. The average time from ARN to the first questionnaire being posted was 1--3 months, with the post colonoscopy questionnaire (for positive participants) sent 1--3 weeks after the procedure.

### Questionnaires

*Demographic Information Survey*: age, gender, postcode (for Index of Relative Socioeconomic Disadvantage (IRSAD), [@bib1]), place of birth, first language, employment status and education level.*Quality of Life -- Short-Form 36*: evaluates physical functioning, physical and emotional role limitations, vitality, mental health, social functioning, body pain, general health and health transition ([@bib23]; [@bib3]). Answers are weighted out of 100. Lower scores indicate poorer outcomes.*Anxiety & Depression* -- Spielberger State-Trait Inventory: measures anxiety, curiosity, anger and depression traits as well as the participant\'s current state with respect to these indices ([@bib24]). The higher the number, the worse the indice.*Multi-Dimensional Health Locus of Control*: includes domains of 'internal control\' and 'power\' (measuring belief in personal control over health) and 'chance\', 'doctor\' and 'other people\' (representing belief that other people or things control one\'s health) ([@bib28]). A higher aggregated score indicates stronger agreement with each domain.*Decision Evaluation Scale applied to CRC screening*: uses a 5-point Likert scale to evaluate the participant\'s level of satisfaction with their decision to undertake CRC screening ([@bib25]). A higher score equals stronger agreement with the item.*Colorectal Cancer Risk*: uses a 7-point Likert scale to evaluate the participant\'s perception of CRC risk (risk perception), confidence in participating in screening (self-efficacy) and response to screening (response efficacy) ([@bib15]). A higher number equals higher risk perception and efficacy.

Analysis
--------

The sample size was calculated assuming 95% probability with 80% power to detect shifts in key outcome scores of 20%. All data were analysed using SPSS v19. As one objective of this study was to identify significant differences in outcomes between groups, analyses were conducted using paired and independent-sample *t*-tests. Chi-square analysis was performed on frequency data. Multivariate regression analyses were undertaken to identify psychosocial constructs jointly associated with test outcomes while controlling for differences in demographic factors between groups.

Results
=======

In all 520 questionnaires were sent ARN (positives=305, negatives=215), with 301 questionnaires returned (positives=165, negatives=136; response rate=58% see [Figure 1](#fig1){ref-type="fig"}).

Sample characteristics
----------------------

The mean age of negatives was greater than that of positives, at 61.8 *vs* 59.5years (*P*=0.009). The positive group had 43% females and 57% males, while the negative group had 53% females and 47% males (*P*=NS). The place of birth for the majority of participants was Australia (69% of positives, 76% of negatives) followed by the United Kingdom (23% of positives, 14% of negatives). Similar patterns in employment status and education qualifications were observed between groups. There was a significant difference between groups for the IRSAD, with more positives living in low IRSAD suburbs (45% *vs* 30% *P*=0.034). The few participants with English as second-language were in the positive group (*P*=0.039). Multivariate regression analysis showed that differences in sample characteristics did not significantly influence study outcomes.

Quality of life
---------------

Positives showed no significant changes in QOL domains post colonoscopy or at 1 year relative to ARN. At both ARN and at 1 year, negatives demonstrated greater physical functioning (*P*=0.016 and 0.017, respectively), vitality (*P*=0.015 and 0.008), mental health (*P*=0.026 and 0.049), social functioning (*P*=0.036 and 0.004), general health (*P*=0.025 and 0.036) and less role limitation related to emotional health problems (*P*=0.012 and 0.020) compared to positives ([Table 1](#tbl1){ref-type="table"}).

Anxiety and depression
----------------------

Positives experienced a significant improvement in the trait depression post colonoscopy (*P*=0.023) and improvements in state anxiety and depression at 1 year (*P*=0.050 and 0.041, respectively), while negatives had a significant improvement in the trait depression (*P*=0.000) at 1 year. ARN and 1-year comparison demonstrated significantly higher (worse) state anxiety (*P*=0.000 and 0.014), anger (*P*=0.005 and 0.004) and depression (*P*=0.011 and 0.000) in positives compared to negatives ([Table 1](#tbl1){ref-type="table"}).

Health locus of control
-----------------------

Post colonoscopy, positives demonstrated a significant improvement in the power domain (*P*=0.042), indicating more self-control over their health. At 1 year, positives felt their health was less reliant on doctors (significant decrease in the doctor domain (*P*=0.033)). There were no significant changes in the negative group or between groups ARN or at 1 year ([Table 1](#tbl1){ref-type="table"}).

Decision evaluation
-------------------

ARN, positives had greater doubtfulness about their screening decision (*P*=0.045) and felt less satisfied about the information they received (*P*=0.036) compared to negatives. Positives experienced a significant decrease in doubt related to their CRC screening decision post colonoscopy (*P*=0.004) and a decrease in wanting information about screening options at 1 year (*P*=0.022), while negatives experienced a significant decrease in satisfaction with information received (*P*=0.012; [Table 1](#tbl1){ref-type="table"}).

Colorectal cancer risk
----------------------

Post colonoscopy, positives reported greater likelihood of developing CRC if they did not participate in screening (*P*=0.005), and increased seriousness of suffering from CRC (*P*=0.022), but less difficulty in participating in ongoing CRC screening (*P*=0.012). Positives also experienced a significant improvement in self-efficacy post colonoscopy (*P*=0.025), which decreased slightly at 1 year (*P*=0.012). Negatives experienced no significant changes in cancer risk perception or self-efficacy at 1 year. ARN and 1-year comparisons demonstrated that negatives rated their likelihood of developing CRC, if they did not participate in screening (*P*=0.002 and 0.000) and in comparison to the average person (*P*=0.002 and 0.039), as lower relative to positives ([Table 1](#tbl1){ref-type="table"}).

Discussion
==========

We believe that this study is one of the most comprehensive assessments of the psychological impacts of FIT CRC screening, demonstrating that while a positive result does cause an element of anxiety, this improves over time. However, anxiety does remain higher than negatives, most likely associated with an increased perception of the risk of developing CRC. Undergoing screening is also associated with an increase in the autonomy of decision making and recognition that surveillance does reduce CRC risk, suggesting that overall there is perhaps a psychological benefit for FIT-positive participants.

Undergoing colonoscopy did not significantly change the QOL domains for positives, which is consistent with the QOL screening studies undertaken by [@bib19] and [@bib21]. This is in contrast to a study by [@bib26] demonstrating statistically significant improvements in mental health, role limitations related to emotions and vitality post colonoscopy in FIT-positive participants. Together these studies strongly indicate that undergoing CRC screening is not detrimental to the screenee\'s QOL.

State anxiety, anger and depression were consistently lower in negatives compared to positives, although state anxiety did decrease in FIT positives post colonoscopy and at 1 year. The reduction in state anxiety within the positive group is consistent with other studies by [@bib6], [@bib20] and a more recent study that included measurements pre FIT and also demonstrated significantly higher mean scores and mood disturbance in FIT positives compared to negatives, with a drop in these same parameters 4 months post testing ([@bib14]).

FIT positives experienced a significant improvement in the HLoC power domain post colonoscopy, indicating that undergoing such a procedure is perhaps an empowering experience in terms of perceived control over one\'s health. Indeed, a sense of self-empowerment and self-efficacy has been demonstrated to positively influence cancer screening behaviour, in terms of decision making, intentions and uptake ([@bib7]; [@bib18]; [@bib17]).

Positives showed significantly higher doubt in relation to their screening decision. This decreased following colonoscopy, probably associated with removal of apprehension about diagnostic outcome. Positives also reported that they would find it less difficult to participate in ongoing CRC screening, with the intention to continue screening after making an initial decision to screen also being supported by [@bib16].

A contrast was seen in CRC risk perception, with negatives reporting significantly less likelihood of developing CRC in comparison to positives both ARN and at 1 year. In addition, positives reported an increase in seriousness of CRC after colonoscopy. This demonstrated discrepancy is of importance, as higher perceived CRC susceptibility is a positive predictor of higher screening intentions ([@bib2]; [@bib8]), while a lower perceived susceptibility is a negative indicator ([@bib27]). This indicates that perhaps negatives require education on their overall CRC risk, with the aim of encouraging participation in future screening.

Limitations
-----------

One limitation of this study is the smaller sample size in comparison to other studies. However, outcomes are congruent with other studies in terms of minimal adverse effects on QOL indicators and the transience of anxiety following a positive result.

This study lacks a 'true\' baseline (i.e. a measure of outcomes prior to CRC screening). Owing to privacy and confidentiality restrictions, researchers are unable to access the Australian register that stores information and co-ordinates the national CRC screening mail-out. Therefore, there is currently no way of obtaining pre-testing data from participants.

Lastly, the sample comprised predominantly those born in Australian or the United Kingdom and may not represent the impact of CRC screening on different cultural groups. Despite these limitations, the study provides new insights into the psychological impacts of FIT-based CRC screening in Australia.

This study was funded by the South Australian Government Strategic Health Research Program.

The authors declare no conflict of interest.
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###### Score changes in SF-36, Spielberger State-Trait Inventory, Health Locus of Control, Decision Evaluation Scales and Colorectal Cancer Risk within and between FIT-positive and FIT-negative groups after result notification, post colonoscopy (FIT positives) and at 1-year follow-up (mean±s.e.m.)

                                                         **FIT positive**     **FIT negative**   **FIT positive** ***vs*** **FIT negative**                                                                                                                                                                           
  --------------------------------------------------- ---------------------- ------------------ -------------------------------------------- ----------------- ------------- ----------------- ----------------- ------------- ------------------------------------- ------------- ---------------------------------- -------------
  **Short-Form 36**                                                                                                                                                                                                                                                                                                   
  Role limitations -- physical                            **76** (±3.2)        **72** (±3.6)                       0.186                       **75** (±4.1)       0.522       **78** (±3.1)     **87** (±2.5)    ***0.016***      **76** (±3.2); **78** (±3.1)          0.511        **75** (±4.1); **87** (±2.5)     ***0.014***
  Health transition                                       **52** (±1.5)        **51** (±1.7)                       0.927                       **55** (±1.6)       0.160       **52** (±1.3)     **56** (±1.2)    ***0.050***      **52** (±1.5); **52** (±1.3)          0.533        **55** (±1.6); **56** (±1.2)        0.785
  Physical functioning                                    **77** (±2.3)        **77** (±2.3)                       0.614                       **75** (±3.0)       0.290       **82** (±1.3)     **82** (±1.5)       0.834         **77** (±2.3); **82** (±1.3)       ***0.016***     **75** (±3.0); **82** (±1.5)     ***0.017***
  Role limitations -- emotional                           **76** (±3.5)        **80** (±3.1)                       0.153                       **78** (±3.9)       0.155       **87** (±2.7)     **88** (±2.3)       0.788         **76** (±3.5); **87** (±2.7)       ***0.012***     **78** (±3.9); **88** (±2.3)     ***0.020***
  Vitality                                                **59** (±2.1)        **59** (±2.0)                       0.911                       **59** (±2.5)       0.298       **66** (±1.6)     **67** (±1.6)       0.980         **59** (±2.1); **66** (±1.6)       ***0.015***     **59** (±2.5); **67** (±1.6)     ***0.008***
  Mental health                                           **74** (±1.6)        **73** (±1.7)                       0.464                       **75** (±2.1)       0.805       **80** (±1.3)     **80** (±1.4)       0.968         **74** (±1.6) ; **80** (±1.3)      ***0.026***     **75** (±2.1); **80** (±1.4)     ***0.049***
  Social functioning                                      **82** (±2.3)        **82** (±2.3)                       1.000                       **81** (±3.1)       0.246       **88** (±1.7)     **90** (±1.7)       0.484         **82** (±2.3); **88** (±1.7)       ***0.036***     **81** (±3.1); **90** (±1.7)     ***0.004***
  General health                                          **67** (±1.9)        **65** (±2.0)                       0.138                       **66** (±2.1)       0.817       **72** (±1.4)     **73** (±1.5)       0.279         **67** (±1.9); **72** (±1.4)       ***0.025***     **66** (±2.1); **73** (±1.5)     ***0.036***
  **Spielberger State/Trait Scale**                                                                                                                                                                                                                                                                                   
  State anxiety                                           **17** (±0.5)        **18** (±0.7)                       0.092                       **16** (±0.5)    ***0.050***    **15** (±0.4)     **14** (±0.4)       0.261         **17** (±0.5); **15** (±0.4)       ***0.000***     **16** (±0.5); **14** (±0.4)     ***0.014***
  State anger                                             **12** (±0.4)        **12** (±0.3)                       0.216                       **12** (±0.5)       0.464       **11** (±0.2)     **11** (±0.2)       0.310         **12** (±0.4); **11** (±0.2)       ***0.005***     **12** (±0.5); **11** (±0.2)     ***0.004***
  State depression                                        **16** (±0.3)        **17** (±0.7)                       0.198                       **16** (±0.6)    ***0.041***    **15** (±0.3)     **14** (±0.4)    ***0.000***      **16** (±0.3); **15** (±0.2)       ***0.002***     **16** (±0.6); **14** (±0.4)     ***0.000***
  Trait depression                                     **16** ([+]{.ul}0.2)    **15** (±0.2)                    ***0.023***                    **11** (±0.3)       0.426       **10** (±0.2)     **9** (±0.2)        0.170      **16** ([+]{.ul}0.2); **10** (±0.3)   ***0.011***     **11** (±0.3); **9** (±0.2)      ***0.003***
  **Health Locus of Control**                                                                                                                                                                                                                                                                                         
  Internal                                                **26** (±0.4)        **25** (±0.4)                       0.461                       **24** (±0.5)       0.058       **24** (±0.4)     **25** (±0.6)       0.280         **26** (±0.4); **24** (±0.4)          0.103        **24** (±0.5); **25** (±0.6)        0.280
  Power                                                   **18** (±0.3)        **19** (±0.3)                    ***0.042***                    **19** (±0.5)       0.139       **18** (±0.3)     **19** (±0.5)       0.137         **18** (±0.3); **18** (±0.3)          0.336        **19** (±0.5); **19** (±0.5)        0.327
  Chance                                                  **21** (±0.4)        **21** (±0.4)                       0.638                       **21** (±0.4)       0.453       **21** (±0.4)     **22** (±0.6)       0.067         **21** (±0.4); **21** (±0.4)          0.555        **21** (±0.4); **22** (±0.6)        0.083
  Doctor                                                  **12** (±0.2)        **13** (+0.2)                       0.129                       **12** (±0.3)    ***0.033***    **12** (±0.2)     **13** (+0.3)       0.223         **12** (±0.2); **12** (±0.2)          0.962        **12** (±0.3); **13** (+0.3)        0.293
  Other people                                             **5** (±0.2)         **6** (±0.2)                       0.090                       **6** (±0.2)        0.964       **6** (±0.2)      **7** (±0.3)        0.187          **5** (±0.2); **6** (±0.2)           0.133         **6** (±0.2); **7** (±0.3)         0.521
  **Decision Evaluation Scale**                                                                                                                                                                                                                                                                                       
  Doubtful about decision                                 **1.7** (±0.1)       **1.3** (±0.1)                   ***0.004***                   **1.4** (±0.1)       0.489      **1.4** (±0.1)    **1.5** (±0.1)       0.618        **1.7** (±0.1); **1.4** (±0.1)      ***0.045***    **1.4** (±0.1); **1.5** (±0.1)       0.712
  More info about options                                 **2.8** (±0.1)       **3.0** (±1.3)                      0.566                      **2.6** (±1.5)    ***0.022***   **2.9** (±0.1)    **2.9** (±0.1)       0.919        **2.8** (±0.1); **2.9** (±0.1)         0.379       **2.6** (±1.5); **2.9** (±0.1)       0.108
  Satisfaction with info                                  **4.6** (±0.1)       **4.7** (±0.1)                      0.378                      **4.6** (±0.1)       0.368      **4.8** (±0.6)    **4.5** (±1.0)    ***0.012***     **4.6** (±0.1); **4.8** (±0.6)      ***0.036***    **4.6** (±0.1); **4.5** (±1.0)       0.655
  Pros and cons of procedure                              **4.5** (±0.1)       **4.7** (±0.1)                      0.218                      **4.6** (±0.1)       0.713      **4.4** (±1.0)    **4.3** (±1.0)       0.159        **4.5** (±0.1); **4.4** (±1.0)         0.319       **4.6** (±0.1); **4.3** (±0.1)    ***0.018***
  **CRC risk perception**                                                                                                                                                                                                                                                                                             
  CRC likelihood if don\'t participate in screening       **3.4** (±0.1)       **3.8** (±0.1)                   ***0.005***                   **3.8** (±0.1)       0.940      **3.0** (±0.1)    **3.0** (±0.1)       0.863        **3.4** (±0.1); **3.0** (±0.1)      ***0.002***    **3.8** (±0.1); **3.0** (±0.1)    ***0.000***
  CRC likelihood compared to average person               **4.0** (±0.1)       **3.8** (±0.1)                   ***0.048***                   **4.0** (±0.1)       0.153      **3.6** (±0.1)    **3.7** (±0.1)       0.533        **4.0** (±0.1); **3.6** (±0.1)      ***0.002***    **4.0** (±0.1); **3.7** (±0.1)    ***0.039***
  Seriousness of CRC                                      **4.2** (±0.1)       **4.4** (±0.1)                   ***0.022***                   **4.4** (±0.1)       0.428      **4.3** (±0.1)    **4.5** (±0.1)       0.119        **4.2** (±0.1); **4.3** (±0.1)         0.544       **4.4** (±0.1); **4.5** (±0.1)       0.493
  Participating in ongoing screening                      **4.8** (±0.1)       **5.2** (±0.1)                   ***0.012***                   **5.1** (±0.1)       0.088      **4.9** (±0.1)    **5.0** (±0.1)       0.552        **4.8** (±0.1); **5.2** (±0.1)      ***0.039***    **5.1** (±0.1); **5.0** (±0.1)       0.426
  Self-efficacy                                           **9.9** (±0.2)      **10.3** (±0.2)                   ***0.025***                   **10.1** (±0.2)   ***0.012***   **10.1** (±0.2)   **10.2** (±0.1)      0.631        **9.9** (±0.2); **10.1** (±0.2)        0.493      **10.1** (±0.2); **10.2** (±0.1)      0.661
  Risk perception                                        **11.7** (±0.2)      **12.0** (±0.2)                      0.095                      **12.1** (±0.2)      0.895      **10.9** (±0.2)   **11.1** (±0.2)      0.462       **11.7** (±0.2); **10.9** (±0.2)     ***0.006***   **12.1** (±0.2); **11.1** (±0.2)   ***0.002***

Abbreviations: ARN=after result notification; CRC=colorectal cancer; post col=post colonoscopy. Bold indicates questionnaire scores and bold italic indicates statistical significance.
